Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Day 100 Recovery of Absolute Number of Inhibitory KIR2DL2 and Activating NKp30 Natural Killer Cells Predicts Survival Post-Autologous Stem Cell Transplantation in Lymphomas
Porrata, Luis F. , Ansell, Stephen M. , Micallef, Ivana N. , Johnston, Patrick B., Paludo, Jonas , Ansell, Stephen M , Johnston, Patrick B. , Villasboas, José C. , Paludo, Jonas , Durani, Urshila , Markovic, Svetomir N.

Biomedicines | August 9, 2024 | Volume: 12 | Issue: 8 | Pages: 1808

10.3390/biomedicines12081808 | PMID 39200272 Get It

The infusion autograft absolute number of inhibitory killer immunoglobulin-like receptor (KIR) 2DL2 and activating natural killer (NK)p30 cells are predictors of clinical outcomes in lymphoma patients undergoing autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT). To assess if the long-term recovery of these NK cell subsets still holds clinical relevance, we set up to investigate their prognostic ability at day 100 post-APBHSCT. This was a retrospective single-institution study including 107 patients from our prior phase III trial who had a clinical assessment at day 100 post-APBHSCT. The median follow-up from day 100 was 168.19 months (interquartile range: 156.85–181.28 months). Patients with day 100 inhibitory KIR2DL2 < 0.08 cells/µL and activating NKp30 ≥ 0.19 cells/µL experienced superior overall survival (OS) and progression-free survival (PFS). A multivariate analysis revealed both the day 100 inhibitory KIR2DL2 [OS: HR = 1.449, 95%CI, 1.231–1.895, p < 0.013; and PFS: HR = 2.069, 95%CI, 1.134–3.775, p < 0.021] and activating NKp30 [OS: HR = 4.985, 95%CI, 2.614–9.506, p < 0.0001; and PFS: HR = 4.661, 95%CI, 2.598–8.393, p < 0.0001] were independent predictors for OS and PFS. Inhibitory KIR2DL2 and activating NKp30 NK cells at day 100 are prognostic immune biomarkers in lymphoma patients treated with APBHSCT.
Communication in the ICU: An Unintended Nocebo Effect?
Guiance, Irene Riestra , Wallace, Lindsey , Hosey, Megan M. , Chitulangoma, Jillene, Philbrick, Kemuel L. , Weiman, Madeline, Schmitt, Emily, Pasko, David, Karnatovskaia, Lioudmila V. , Riestra Guiance, Irene, Niven, Alexander, Hosey, Megan , Philbrick, Kemuel, Karnatovskaia, Lioudmila , Wallace, Lindsey , Varga, Katalin , Niven, Alexander S. , Gajic, Ognjen

Journal of Patient Experience | August 9, 2024 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/23743735241272148 | PMID 39130130 Get It

To identify medical phrases utilized by the critical care team that may have an unintended impact on the critically ill patient, we administered an anonymous survey to multi-professional critical care team members. We elicited examples of imprecise language that may have a negative emotional impact on the critically ill. Of the 1600 providers surveyed, 265 offered 1379 examples (912 unique) which were clustered into 5 categories. Medical jargon (eg, “riding the vent”) was most prevalent (n = 549). There were 217 negative suggestions (eg, “you will feel a stick and a burn”). Hyperboles (eg, “black cloud”) were common (n = 198) while homonyms (ie “he fibbed”) accounted for 150 examples. Phrases such as “code brown in there” were categorized as metonyms (n = 144). 121 metaphors/similes (eg, “rearranging deck chairs on the Titanic”) were provided. Phrases that have the potential to negatively impact critically ill patient perceptions are commonplace in critical care practice. Whether these everyday communication habits lead to an unintended nocebo effect on mental health outcomes of the critically ill deserves further study.
Clinical Utility of Protein Language Models in Resolution of Variants of Uncertain Significance in KCNQ1, KCNH2 , and SCN5A Compared With Patch-Clamp Functional C
Ye, Dan , Garmany, Ramin , Martinez-Barrios, Estefania, Gao, Xiaozhi , Neves, Raquel , Tester, David J. , Bains, Sahej , Zhou, Wei , Giudicessi, John R. , Ackerman, Michael J. , Neves, Raquel Almeida Lopes , Bains, Sahej , Ye, Dan , Garmany, Ramin

Circulation: Genomic and Precision Medicine | August 9, 2024 | Volume: 17 | Issue: 5 | Pages: No page available

10.1161/circgen.124.004584 | PMID 39119706 Get It

BACKGROUND: Genetic testing for cardiac channelopathies is the standard of care. However, many rare genetic variants remain classified as variants of uncertain significance (VUS) due to lack of epidemiological and functional data. Whether deep protein language models may aid in VUS resolution remains unknown. Here, we set out to compare how 2 deep protein language models perform at VUS resolution in the 3 most common long-QT syndrome–causative genes compared with the gold-standard patch clamp. METHODS: A total of 72 rare nonsynonymous VUS (9 KCNQ1, 19 KCNH2 , and 50 SCN5A ) were engineered by site-directed mutagenesis and expressed in either HEK293 cells or TSA201 cells. Whole-cell patch-clamp technique was used to functionally characterize these variants. The protein language models, evolutionary scale modeling, version 1b and AlphaMissense, were used to predict the variant effect of missense variants and compared with patch clamp. RESULTS: Considering variants in all 3 genes, the evolutionary scale modeling, version 1b model had a receiver operating characteristic curve–area under the curve of 0.75 ( P =0.0003). It had a sensitivity of 88% and a specificity of 50%. AlphaMissense performed well compared with patch-clamp with an receiver operating characteristic curve-area under the curve of 0.85 ( P <0.0001), sensitivity of 80%, and specificity of 76%. CONCLUSIONS: Deep protein language models aid in VUS resolution with high sensitivity but lower specificity. Thus, these tools cannot fully replace functional characterization but can aid in reducing the number of variants that may require functional analysis.
Primary Care Productivity and Patient Satisfaction Community Practice: What is the Relationship?
Howell, Thomas G., Jr., Thomas G. Howell

Patient Experience Journal | August 9, 2024 | Volume: 11 | Issue: 2 | Pages: 27-35

10.35680/2372-0247.1948 Get It

Research has shown a consistent positive association between patient and provider experience and improved patient outcomes and safety. There is a belief that patient satisfaction and physician productivity are competing interests. The relationship for primary care physicians, in a Midwest Health system was evaluated as part of this project. Data from Press Ganey patient satisfaction surveys on likelihood of recommending the practice and the physician were compared between primary care physicians in the top quartile of average monthly patient visits and those that were in the three lower quartiles. A secondary analysis of patient satisfaction scores related to continuous years of service was also performed. Results of a multi-level logistic regression analysis showed a statistically significant difference between quartiles on average monthly visits and the likelihood of receiving a top box score on recommendation of the practice, but not the provider. The odds ratio was 0.7 for lower quartiles compared to highest quartile of visits. There was not a statistically significant difference for the categories of continuous years of service. On the question of recommending the physician, the odds ratios were not different, although there was a significant difference for the categories of years of service, with those between 0-5 years having a 0.62 odds ratio of a top box score compared to greater than 10 years. The results would tend to refute the belief that patient satisfaction must be sacrificed for physician productivity.
Cochlear Implantation Outcomes in Patients With Sporadic Inner Ear Schwannomas With and Without Simultaneous Tumor Resection
Nassiri, Ashley M. , Staricha, Kelly L. , Neff, Brian A., Driscoll, Colin L. W., Link, Michael J. , Carlson, Matthew L. , Staricha, Kelly

Otology & Neurotology | August 9, 2024 | Volume: 45 | Issue: 9 | Pages: 1051-1054

10.1097/mao.0000000000004268 | PMID 39118256 Get It

Objectives Describe a single institution's cochlear implant outcomes for patients with inner ear schwannomas (IES) in the setting of various tumor management strategies (observation, surgical resection, or stereotactic radiosurgery [SRS]). Study Design Single-institution retrospective review. Patients Patients diagnosed with isolated, sporadic IES who underwent cochlear implantation (CI). Interventions CI with or without IES treatment. Main Outcome Measures Speech perception outcomes, tumor status. Results Twelve patients with IES underwent CI with a median audiologic and radiologic follow-up of 12 months. Six patients underwent complete resection of the tumor at the time of CI, four underwent tumor observation, and two underwent SRS before CI. At 1 year after CI for all patients, the median consonant–nucleus–consonant (CNC) word score was 55% (interquartile range, 44–73%), and the median AzBio sentence in quiet score was 77% (interquartile range, 68–93%). Overall, those with surgical resection performed similarly to those with tumor observation (CNC 58 versus 61%; AzBio in quiet 74 versus 91%, respectively). Patients who underwent tumor resection before implantation had a wider range of speech performance outcomes compared with patients who underwent tumor observation. Two patients had SRS treatment before CI (10 months previous and same-day as CI) with CNC word scores of 6 and 40%, respectively. Conclusions Patients with IES who underwent CI demonstrated similar speech performance outcomes (CNC 56% and AzBio 82%), when compared with the general cochlear implant population. Patients who underwent either tumor observation or surgical resection performed well after CI.
Neck apposition is a key factor for aneurysm occlusion after Woven EndoBridge device embolization
Cortese, Jonathan , Juhász, J , Rodriguez‐Erazú, Fernanda , Ghozy, Sherief , Bayraktar, Esref Alperen , Zarrintan, Armin , Ueki, Yasuhito , Caroff, Jildaz , Kallmes, David F. , Kadirvel, Ramanathan , Zarrintan, Armin , Caroff, Jildaz , Spelle, Laurent , Kadirvel, Ram , Ghozy, Sherief , Cortese, Jonathan , Bayraktar, Esref Alperen , Mihalea, Cristian , Spelle, Laurent

Journal of NeuroInterventional Surgery | August 8, 2024 | Volume: 17 | Issue: 10 | Pages: 1083-1088

10.1136/jnis-2024-022155 | PMID 39122254 Get It

Background Sealing of the aneurysm neck with a Woven EndoBridge (WEB) device is recommended for disrupting the blood flow inside the aneurysm. This study investigates the relationship between WEB neck apposition and aneurysm occlusion rates. Methods Aneurysms treated with a WEB from March 2017 to May 2022 at a single center were included. WEB neck apposition (poor/good) and WEB protrusion (yes/no) were evaluated on post-detachment high resolution cone beam CT images. Angiographic occlusion was assessed with the Bicêtre Occlusion Scale score (BOSS). Univariate and multivariable analysis tested the association between neck apposition and occlusion rates. Results The study included 159 aneurysms in 141 patients (mean age 55.8±11.2 years; 64.2% women). Good neck apposition and protrusion were noted in 123 (77.4%) and 30 (18.9%) cases, respectively. Inter-rater agreements were good for neck apposition (κ=0.75) and protrusion (κ=0.78). Complete and adequate occlusion was achieved in 104 (65%) and 130 (82%) cases, respectively (median follow-up 18 months). Good neck apposition was a strong independent predictor for both adequate (adjusted OR (aOR)=5.9, 95% CI 2.4 to 14.9; P<0.001) and complete occlusion (aOR=7.1, 95% CI 3.0 to 18.1; P<0.001). Protrusion was more frequent in the adequate occlusion group versus the aneurysm recurrence group without reaching statistical significance (P=0.06), but was associated with more thromboembolic complications (9/30 (30%) vs 12/129 (9%); P<0.01). WEB shape modification was significantly greater in poor apposition cases (P=0.03). Conclusions Achieving good neck apposition of the WEB strongly predicts aneurysm occlusion during follow-up. WEB protrusion should be minimized due to the increase in thromboembolic risk with limited impact on aneurysm occlusion.
KCNQ1 suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome
Bains, Sahej , Giammarino, Lucilla , Nimani, Saranda , Alerni, Nicolò , Tester, David J. , Kim, C.S. John, Christoforou, Nicolas , Louradour, Julien , Beslac, Olgica, Barbieri, Miriam , Matas, Lluis , Hof, Thomas , López, Rubén , Perez‐Feliz, Stefanie , Casalta, L.G. Garcia, Jurgensen, Jacqulyn, Bego, Mariana G. , Keyes, Lisa R., Owens, Jane , Pinkstaff, Jason, Koren, Gideon , Zehender, Manfred, Brunner, Michael, Casoni, Daniela , Brooks, Gabriel , Ackerman, Michael J. , Odening, Katja E. , Brunner, Michael , Praz, Fabien , Haeberlin, Andreas , Ackerman, Michael J , Odening, Katja E , Bains, Sahej , Horváth, András , Parodi, Chiara, Barry, Michael A. , Praz, Fabien

European Heart Journal | August 8, 2024 | Volume: 45 | Issue: 36 | Pages: 3751-3763

10.1093/eurheartj/ehae476 | PMID 39115049 Get It

Abstract Background and Aims Type 1 long QT syndrome (LQT1) is caused by pathogenic variants in the KCNQ1-encoded Kv7.1 potassium channels, which pathologically prolong ventricular action potential duration (APD). Herein, the pathologic phenotype in transgenic LQT1 rabbits is rescued using a novel KCNQ1 suppression-replacement (SupRep) gene therapy. Methods KCNQ1-SupRep gene therapy was developed by combining into a single construct a KCNQ1 shRNA (suppression) and an shRNA-immune KCNQ1 cDNA (replacement), packaged into adeno-associated virus serotype 9, and delivered in vivo via an intra-aortic root injection (1E10 vg/kg). To ascertain the efficacy of SupRep, 12-lead electrocardiograms were assessed in adult LQT1 and wild-type (WT) rabbits and patch-clamp experiments were performed on isolated ventricular cardiomyocytes. Results KCNQ1-SupRep treatment of LQT1 rabbits resulted in significant shortening of the pathologically prolonged QT index (QTi) towards WT levels. Ventricular cardiomyocytes isolated from treated LQT1 rabbits demonstrated pronounced shortening of APD compared to LQT1 controls, leading to levels similar to WT (LQT1-UT vs. LQT1-SupRep, P &lt; .0001, LQT1-SupRep vs. WT, P = ns). Under β-adrenergic stimulation with isoproterenol, SupRep-treated rabbits demonstrated a WT-like physiological QTi and APD90 behaviour. Conclusions This study provides the first animal-model, proof-of-concept gene therapy for correction of LQT1. In LQT1 rabbits, treatment with KCNQ1-SupRep gene therapy normalized the clinical QTi and cellular APD90 to near WT levels both at baseline and after isoproterenol. If similar QT/APD correction can be achieved with intravenous administration of KCNQ1-SupRep gene therapy in LQT1 rabbits, these encouraging data should compel continued development of this gene therapy for patients with LQT1.
Utility of CT and MRI in Cardiac Electrophysiology
Bugenhagen, Scott M. , Kolluri, Nikhil , Tan, Nicholas Y. , Morris, Michael F. , Bugenhagen, Scott , Rajiah, Prabhakar , Rajiah, Prabhakar

RadioGraphics | August 8, 2024 | Volume: 44 | Issue: 9 | Pages: No page available

10.1148/rg.230222 | PMID 39115996 Get It

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis
Tefferi, Ayalew , Barosi, Giovanni , Hernández‐Boluda, Juan Carlos , Bose, Prithviraj , Döhner, Konstanze , Gangat, Naseema , Garcia, Jacqueline S. , Gisslinger, Heinz , Gupta, Vikas , Harrison, Claire , Loscocco, Giuseppe Gaetano , Mora, Barbara , Odenike, Olatoyosi, Pardanani, Animesh , Patel, Anand , Pemmaraju, Naveen , Rampal, Raajit K. , Sirhan, Shireen , Vachhani, Pankit , Vannucchi, Alessandro M., Barbui, Tiziano , Hernández-Boluda, Juan Carlos , Bose, Prithviraj , Gangat, Naseema , Garcia, Jacqueline S , Gupta, Vikas , Hexner, Elizabeth , Hobbs, Gabriela S , Koschmieder, Steffen , Kuykendall, Andrew , Loscocco, Giuseppe Gaetano , Mascarenhas, John , Masarova, Lucia , Mesa, Ruben , Oh, Stephen T , Patel, Anand , Pemmaraju, Naveen , Rambaldi, Alessandro , Szuber, Natasha , Vachhani, Pankit , Barbui, Tiziano , Passamonti, Francesco , Ellis, Martin H. , Gotlib, Jason , Guglielmelli, Paola , Hexner, Elizabeth O. , Hobbs, Gabriela , Kiladjian, Jean‐Jacques , Koschmieder, Steffen , Kröger, Nicolaus , Mascarenhas, John , Masárová, Lucia , Mesa, Ruben A. , Odenike, Olatoyosi , Oh, Stephen T. , Rambaldi, Alessandro , Szuber, Natasha , Talpaz, Moshe

Blood | August 8, 2024 | Volume: 144 | Issue: 17 | Pages: 1813-1820

10.1182/blood.2024025802 | PMID 39116296 Get It

Abstract With emerging new drugs in myelofibrosis (MF), a robust and harmonized framework for defining the severity of anemia and response to treatment will enhance clinical investigation and facilitate interstudy comparisons. Accordingly, the lead authors on the 2013 edition of the International Working Group–European LeukemiaNet (IWG-ELN) response criteria in MF were summoned to revise their document with the intent to (1) account for gender-specific differences in determining hemoglobin levels for eligibility criteria; (2) revise the definition of transfusion-dependent anemia (TDA) based on current restrictive transfusion practices; and (3) provide a structurally simple and easy to apply response criteria that are sensitive enough to detect efficacy signals (minor response) and also account for major responses. The initial draft of the 2024 IWG-ELN proposed criteria was subsequently circulated around a wider group of international experts and their feedback incorporated. The proposed articles include new definitions for TDA (≥3 units in the 12 weeks before study enrollment) and hemoglobin thresholds for eligibility criteria (&lt;10 g/dL for women and &lt;11 g/dL for men). The revised document also provides separate (TDA vs non-TDA) and graded (major vs minor response) response criteria while preserving the requirement for a 12-week period of screening and observation on treatment.
A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol
Palmisiano, Neil , Lee, Ju‐Whei , Claxton, David F. , Paietta, Elisabeth , Park, Jae H. , Podoltsev, Nikolai A. , Atallah, Ehab , Schaar, Dale , Dinner, Shira, Webster, Jonathan , Luger, Selina M. , Litzow, Mark R. , Palmisiano, Neil D , Alkhateeb, Hassan B , Podoltsev, Nikolai , Atallah, Ehab L , Webster, Jonathan A , Luger, Selina M , Claxton, David F , Alkhateeb, Hassan B.

eJHaem | August 8, 2024 | Volume: 5 | Issue: 5 | Pages: 951-956

10.1002/jha2.991 | PMID 39415930 Get It

AbstractIntroductionRelapsed or refractory (r/r) acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) remains a therapeutic challenge. Preclinical data in both B‐ and T‐ALL suggests synergy of venetoclax (VEN) with vincristine (VCR). We designed a phase I/II trial (EA9152) of the combination of L‐VCR and VEN for patients with r/r B‐or T‐cell ALL or LL. Here, we report the safety and efficacy outcomes of the phase I portion of this trial (NCT03504644).MethodsIn a 3+3 dose escalation design, r/r ALL subjects were given single‐agent VEN doses reaching 400, 600, or 800 mg for the three respective dose levels. Weekly L‐VCR at 2.25 mg/m2 IV was started on D15 of cycle 1. The primary phase I objective was to determine the maximum tolerated dose (MTD) of the combination.ResultsAmong the 18 patients in phase I, grade ≥ 3 treatment‐related adverse events were reported in 89% of treated patients. Two patients (two of three) at dose level 3 experienced dose‐limiting toxicities. Therefore, the MTD of the combination was determined to be dose level 2 (VEN 600 mg). Twenty‐two percent of evaluable patients (N = 4) achieved a complete response, with two of them showing no evidence of measurable residual disease (MRD).ConclusionThe combination of VEN and L‐VCR was found to be safe for patients with r/r ALL and encouraging preliminary efficacy, including MRD negative responses. With the removal of L‐VCR from the US market, the phase 2 portion of this trial is actively enrolling with vincristine sulfate.